Procyrion is developing what it says is the first catheter-deployed micropump for the heart. It's now nabbed a $10 million Series B round to back clinical development of its tiny, chronic heart failure device that consists of a continuous flow pump that is mounted via the femoral artery inside the heart to the descending thoracic aorta. Once deployed, its self-expanding anchors fix the pump to the aortic wall.